Good clinical response to imatinib mesylate in atypical thymic carcinoid with KIT overexpression

Journal of Clinical Oncology

Volumn 29, Issue 1, 2011, Pages

  Hamada, Satoshi ^a   Masago, Katsuhiro ^a   Mio, Tadashi ^a   Hirota, Seiichi ^b   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CHROMOGRANIN; CISPLATIN; CYTOKERATIN AE1; CYTOKERATIN AE3; ETOPOSIDE; IMATINIB; KERATIN; KI 67 ANTIGEN; STEM CELL FACTOR RECEPTOR; SYNAPTOPHYSIN;

ADULT; ARTICLE; CARCINOID; CASE REPORT; DYSPNEA; EXON; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THORAX RADIOGRAPHY; THYMUS CANCER; THYMUS CARCINOID;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; THYMOMA; THYMUS NEOPLASMS;

EID: 79951966688     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.2455     Document Type: Article

References (12)

1. Rosai J, Higa E: Mediastinal endocrine neoplasm, of probable thymic origin, related to carcinoid tumor: Clinicopathologic study of 8 cases. Cancer 29:1061-1074, 1972
2. Gielda BT, Peng R, Coleman JL, et al: Treatment of early stage thymic tumors: Surgery and radiation therapy. Curr Treat Options Oncol 9:259-268, 2008
3. Dham A, Truskinovsky AM, Dudek AZ: Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: A case report. J Thorac Oncol 3:94-97, 2008
4. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002 (Pubitemid 34879334)
5. Waller CF: Imatinib mesylate. Recent Results Cancer Res 184:3-20, 2010
6. Liegl-Atzwanger B, Fletcher JA, Fletcher CD: Gastrointestinal stromal tumors. Virchows Arch 456:111-127, 2010
7. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580, 1998 (Pubitemid 28067289)
8. Kindblom LG, Remotti HE, Aldenborg F, et al: Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259-1269, 1998 (Pubitemid 28221878)
9. Hornick JL, Fletcher CD: The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 38:679-687, 2007 (Pubitemid 46560810)
10. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al: CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 11:728-734, 1998 (Pubitemid 28381606)
11. Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813-3825, 2004 (Pubitemid 41095223)
12. Rinke A, Müller HH, Schade-Brittinger C, et al: Placebo-controlled, doubleblind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 27:4656-4663, 2009